Welcome to our dedicated page for NuVasive news (Ticker: NUVA), a resource for investors and traders seeking the latest updates and insights on NuVasive stock.
NuVasive, Inc. (NASDAQ: NUVA) is a leader in spine technology innovation, dedicated to transforming spine surgery with minimally disruptive, procedurally integrated solutions. Headquartered in San Diego, NuVasive aims to advance surgical care and improve patient outcomes through its extensive product portfolio and global reach.
The company’s core offerings include surgical access instruments, spinal implants, fixation systems, biologics, and software for surgical planning. NuVasive also provides navigation and imaging solutions, magnetically adjustable implant systems for both spine and orthopedics, and intraoperative neuromonitoring technology and services. With an emphasis on speed of innovation, NuVasive continually develops new products to meet the evolving needs of spine surgeons, hospitals, and patients.
NuVasive has shown robust financial performance, with over $1 billion in net sales and operations in more than 50 countries. The company's recent achievements include a 2.4% increase in total net sales for the second quarter of 2023, reaching $317.8 million. This growth is driven by the adoption of new products and higher procedural volumes in the U.S.
The company is on the path to combining with Globus Medical, which is anticipated to drive further value creation for shareholders and expand its impact on improving patient lives globally. This merger is expected to enhance NuVasive's ability to deliver innovative and clinically proven outcomes.
NuVasive also emphasizes corporate social responsibility through initiatives like the NuVasive Spine Foundation®, which provides life-changing spinal surgery to disadvantaged communities, and other patient-to-patient support programs.
For more information, visit www.nuvasive.com.
NuVasive, Inc. (NASDAQ: NUVA), a leader in spine technology innovation, will participate in several global spine conferences from April to May 2023. Highlights include the 52nd Annual Meeting of the Japanese Society for Spinal Surgery in Sapporo and BritSpine 2023 in Scotland, where the company will showcase its X360 and Complex portfolios. CEO Chris Barry emphasized the importance of collaboration with influential societies to enhance spine care. Other conferences include the AANS Annual Meeting in Los Angeles and the Pediatric Orthopaedic Society of North America Annual Meeting in Nashville. NuVasive aims to showcase its innovative surgical solutions and celebrate two decades of the XLIF procedure at these events.
NuVasive, Inc. (NASDAQ: NUVA) announced on March 20, 2023, that it received 510(k) clearance from the FDA for its Precice limb lengthening solution to include pediatric patients. This expansion allows the innovative technology to benefit a broader patient demographic. The Precice system, which has been successfully implanted in over 15,000 cases globally, is designed to non-invasively lengthen limbs and reduce the need for further surgeries. With more than 100 peer-reviewed studies supporting its effectiveness, the new indication is critical for pediatric orthopedic practices, enhancing treatment options for those with limb length discrepancies.
NuVasive (NASDAQ: NUVA), a leader in spine technology, will participate in the 2023 Spine Summit from March 16-19 in Miami and the International Meeting on Advanced Spine Techniques (IMAST) from March 22-25 in Dublin. CEO Chris Barry highlighted NuVasive's commitment to clinically validated solutions, celebrating 20 years of its XLIF procedure. At these conferences, NuVasive will showcase its products, including the Pulse platform, at booth #228 and stand 6. Key activities include a product demo on March 16 and a workshop on March 23 featuring advanced strategies for complex spine cases.
FAQ
What is the market cap of NuVasive (NUVA)?
What does NuVasive, Inc. specialize in?
Where is NuVasive headquartered?
What are some of NuVasive's core products?
How did NuVasive perform in the second quarter of 2023?
Is NuVasive involved in any mergers or acquisitions?
How does NuVasive contribute to social responsibility?
What is the mission of NuVasive, Inc.?
In how many countries does NuVasive operate?
What recent financial milestone has NuVasive achieved?
Where can I find more information about NuVasive?
